JAMA 7 Dec 2011 Vol 306 2331 Over the period I have been writing these reviews, rheumatology has moved from being a rather sleepy discipline to being a hotbed of innovation, largely thanks to the arrival of tumour necrosis factor (TNF)-α antagonists. Known rather quaintly as “biologicals,” these drugs inspired fear when first used because […]
Richard Lehman’s journal review – 12 December 2011